The presence of FDG+/PSMA- lesions in patients suffering from prostate carcinoma has been confirmed as a negative prognostic factor associated with a poorer response to [177Lu]-PSMA-617 treatment. This evidence concerns the gene FOLH1 and prostate carcinoma.